Further RWD studies with a larger sample size and an extended follow-up period is required to verify the current study findings and to evaluate long-term safety of DPP-4 inhibitors and SGLT-2 inhibitors in terms of new-onset infections when combined with insulin in later-stage T2DM patients. This evidence concerns the gene INS and infection.